The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Sionna salvages AbbVie assets, teeing up dual combo assault on cystic fibrosis Vertex already sells its triple combination therapies Trikafta and Alyftrek for use in patients with F508del mutations.

Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 newly eligible U.S. patients. Suzetrigine for acute pain aligns with NOPAIN Act ...

The fixed-dose triple-combination therapy, dubbed ‘vanza triple’, is set to build on the success of Vertex’s top-selling combination of elexacaftor, tezacaftor and ivacaftor (Trikafta ...

Sewell wants the drug Trikafta, a life-changing medicine that could see Mila’s future immediately brighten, to be made available for children aged six to 11. Currently, the drug costs $250,000 per ...

Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.